- Details
- Alicia Morgans welcomes Boris Hadaschik to discuss the implications of using PSMA PET in non-metastatic castration-resistant prostate cancer treatment. Their focus lies on Dr. Hadaschik's presentation examining the long-term outcomes and clinical implications of this technology. His study refers to a 2019 dataset involving 200 men diagnosed with high-risk non-metastatic CRPC. Dr. Hadaschik explain...
|
- Details
- Alicia Morgans and Daniel Sentana Lledo discuss a groundbreaking analysis on data from the CHAARTED study that examined how quality of life impacts survival in metastatic hormone-sensitive prostate cancer patients. Interestingly, patients with better quality of life scores at three months exhibited longer survival times. However, the role of docetaxel (a chemotherapeutic) treatment in this finding...
|
- Details
- Alicia Morgans hosts Tian Zhang to present an update from her presentation on the STARTAR trial, focusing on treatment intensification for high-risk prostate cancer with biochemical recurrence. STARTAR builds on an earlier trial, STREAM, by combining hormone deprivation with apalutamide, salvage radiation, and six cycles of docetaxel. The study focused on patients with Gleason 7 with nodal positiv...
|
- Details
- Rafee Talukder discusses his presentation on his research into the effects of MTAP loss on survival rates among advanced urothelial cancer patients undergoing immunotherapy. With the help of an extensive international database, his team found that patients with this MTAP loss exhibited worse observed response rates and a trend toward poorer progression-free survival. In addition, the conversation...
|
- Details
- Zach Klaassen hosts Khalid Alkhatib to discuss the mental health of testicular cancer patients. Dr. Alkhatib shares findings from his study, explaining that the disease impacts a younger demographic, making these patients more susceptible to anxiety and depression. The research revealed that the patients' anxiety and depression levels did not improve over time after active treatment, contrary to t...
|
- Details
- Stacy Loeb shares her significant research on the impact of plant-based diets on prostate cancer risk. The conversation pivots around Dr. Loeb's study which builds on earlier findings that higher plant-based food consumption correlates with lower fatal prostate cancer risk. Her newer research explores the potential benefits of such diets on quality-of-life outcomes post-diagnosis, especially with...
|
- Details
- Alicia Morgans hosts a discussion with William Hall and Rana McKay to discuss SAMURAI, the first cooperative group study that randomizes patients with kidney cancer between radiation and no radiation. Dr. Hall points out how radiation therapy has evolved over the past 15 years, offering high doses with millimeter accuracy that precisely targets malignancy while avoiding normal tissue. This evoluti...
|
- Details
- Petros Grivas hosts a conversation with Hiba Khan, who has earned the prestigious ASCO Young Investigator Award for her work on financial toxicity in prostate cancer patients. Dr. Khan discusses the increasing cost of cancer treatments and the financial hardships that patients experience. This topic is also central to her review article published in the Journal of Clinical Oncology, which offers g...
|
- Details
- Andrea Miyahira interviews JJ Haijing Zhang on her research exploring the genomic alterations in prostate cancer patients exposed to Agent Orange. Agent Orange, an herbicide used by the US military during the Vietnam War, is linked to various health toxicities, including prostate cancer. Dr. Zhang's study aims to identify any specific somatic alterations related to Agent Orange exposure. The resea...
|
- Details
- In this discussion, Alicia Morgans interviews Ravi Parikh about his session on interventions to prevent or mitigate frailty in prostate cancer patients. Dr. Parikh emphasizes the necessity of screening for frailty and tailoring treatment strategies for older patients who may experience different side effects. He elaborates on strategies such as prehabilitation before prostate cancer surgery and ad...
|
